Management of Chronic Kidney Disease Stages 1–3
Clinical Bottom Line: Risk for ESRD in Patients With CKD Stages 1–3 Treated With Other Interventions
There was low-strength evidence that the risk for end-stage renal disease (ESRD) was similar for the remaining comparisons reviewed in the comparative effectiveness review, which included a beta-blocker, a calcium channel blocker (CCB), or a statin versus a control or placebo; a CCB versus a beta-blocker; strict versus standard blood pressure control; or a low-protein versus a usual diet or a carbohydrate-restricted, low-iron-available, polyphenol-enriched diet.
Keywords: end-stage renal disease | ESRD | chronic kidney disease | statin | calcium channel blocker | beta-blocker | diet
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.